Quantum Biology DAO is a BioDAO funding a corner of science most drug-focused DeSci projects never touch: quantum biology, the study of how quantum-mechanical effects – coherence, entanglement, spin – shape processes inside living cells. Where VitaDAO (longevity), CryoDAO (biostasis), and Curetopia (rare disease) each organise around a therapeutic goal, Quantum Biology DAO organises around a physical question and the instrument needed to answer it. It launched publicly in October 2024 out of research originally based at UCLA, and is part of the BIO Protocol (bio.xyz) network of decentralized-science DAOs.
The DAO was admitted to the BIO Incubator's second cohort on 17 October 2024, alongside Long COVID Labs and Curetopia – the three early admissions that seeded Cohort 2.
The organisation is really three bodies under one brand, and keeping them apart is necessary to read anything about it accurately: the DAO (token, treasury, votes) at quantumbiology.xyz; the Quantum Biology Institute, a US non-profit that employs the scientists and runs the labs, at quantumbiology.org; and the Quantum Biology Incubator, a Delaware C-corporation chartered to spin quantum-biology research into companies, at quantumbiology.inc. The DAO does not do science. It votes on money that the Institute spends, and the split shows up in the record below: the two halves have kept very different rhythms.
Quantum biology asks whether biological systems exploit quantum effects that survive the warm, wet, noisy interior of a cell – long assumed too chaotic to preserve quantum states. The DAO's stated aim is to understand the physics behind weak magnetic-field effects so that cellular processes can be deliberately influenced: the team names oxidation rates, cellular repair, and cell-division rates as targets. If weak, precisely-tuned magnetic fields can nudge these processes, the applications span health and longevity, biomanufacturing, and drug discovery.
This is deliberately upstream, high-risk basic science – the kind that struggles for grant funding precisely because it questions a settled assumption. That funding gap is exactly the problem DeSci exists to attack.
Most BioDAO pages in this directory describe a research programme. This one has a published dataset to point at, which makes it unusually easy to check. The Institute's first result is a preprint posted to bioRxiv on 13 October 2024 and revised on 16 October: Weak magnetic field effects in biology are measurable – accelerated Xenopus embryogenesis in the absence of the geomagnetic field (doi 10.1101/2024.10.10.617626), by A. Lodesani, G. Anders, L. Bougas, T. Lins, D. Budker, P. Fierlinger and C. D. Aiello, with Aiello corresponding for the Quantum Biology Institute. Two of the authors are the DAO's own principals: Anders is its CEO, Lodesani is now the Institute's COO.
The claim is narrower than the headline. The authors report that Xenopus laevis embryos develop measurably faster inside an engineered hypomagnetic enclosure of less than 1 nT than in Earth's ambient field of roughly 50 µT, with effects visible from one day post-fertilization, and they explicitly note that no definitive biophysical mechanism accounts for it – the quantum explanation is the one they favour, not the one they demonstrate. The stated purpose of the experiment is to settle the reality of the effect, not its cause.
The open-science claim holds up on inspection. All data and analysis code sit in a public MIT-licensed repository, Quantum-Biology-Institute/Weak-magnetic-field-effects-in-biology-are-measurable, created 18 September 2024 and last pushed 11 October 2024, and the preprint is CC-BY. What has not happened is peer review: bioRxiv's own record still lists no journal publication for the preprint, twenty-three months after v2 (bioRxiv's publication API, checked 19 September 2026). For a DAO whose pitch is that community capital can fund science conventional funders skip, the gap between a released dataset and a reviewed paper is the part of the thesis still outstanding – a general point taken up in DeSci funding.
The DAO's flagship project is a quantum microscope – an instrument built to observe quantum phenomena happening in real time inside living cells, developed in partnership with the Quantum Biology Institute, a US non-profit. Building the tool is the point: much of quantum biology has been stuck on the lack of instruments that can measure quantum states in a biological sample without destroying them. Funding an instrument rather than a molecule makes Quantum Biology DAO structurally distinct from every IP-NFT-based BioDAO in this directory, which fund a research asset that resolves to intellectual property.
The underlying research raised roughly $3M in its first three years from government and private sources at UCLA before moving into the DAO structure. The Institute now runs its own labs from a Los Angeles headquarters, and in April 2025 announced a research partnership with the J. Craig Venter Institute to study how microbial model organisms respond to weak magnetic fields, using JCVI's genomics and multiomics capability. Its funding case is that the shielded enclosures and spectroscopic tools it is building will be shared experimental infrastructure available to researchers across institutions rather than a private asset – which is the specific reason a non-profit, not the Incubator, receives the DAO's grant money.
Quantum Biology DAO is co-founded by Clarice Aiello (Chief Scientific Officer) and Geoff Anders (Chief Executive Officer). Aiello is a physicist who led the quantum-biology research group at UCLA; Anders founded the research organisation Leverage. Naming a credentialed principal investigator, rather than pseudonymous stewards, is characteristic of the bio.xyz BioDAO model, where a real lab sits behind the token.
The Institute has since built out a separate officer team, and the two sets of titles are easy to conflate. As of the April 2026 grant announcement, the Institute's CEO is Todd Thaxton and its COO is Alessandro Lodesani, with Aiello as Chair of the Board and President of the Scientific Advisory Board rather than in an executive role; Brian Ross is named as a research scientist working in the Institute's molecular biology lab. Aiello remains the public face of the science – she was billed on the evidence-based longevity panel at SynBioBeta 2026 in San Jose on 7 May 2026.
Quantum Biology DAO held its token generation event in January 2025 on the BIO Protocol launchpad – the QBIO/WETH auction (#560). $QBIO is a governance and funding token, not equity: like other bio.xyz BioDAOs it carries the right to vote on research direction and grant allocation, curated by $BIO holders who stake into and co-own the BioDAO through the launchpad.
Read on-chain, the token is two contracts rather than one. QBIO (0x3E6A…9bDE, 18 decimals) reports a total supply of 403,844,211, read at Ethereum block 26,014,146 on 19 September 2026. The figure is not fixed and moves both ways: earlier reads gave 404,185,232 and then 404,611,730 on 27 August 2026. Alongside it sits vQBIO, the “QBIO Vesting Token” (0x637b…0868), supply 150,000,000 – a separate, non-tradable claim representing locked allocations. Both are counted for governance, which matters enormously and is taken up in the next section.
The Solana leg does not vote. Following an on-chain vote in January 2025, QBIO was bridged to Solana in March 2025 via Portal Bridge, tradable on Raydium, with the DAO citing access and liquidity. The wrapped mint qbioCGDn…m4LZ8 currently holds 25,795,697 QBIO, about 6.4% of the Ethereum supply. But both of the DAO's Snapshot voting strategies are erc20-balance-of calls against Ethereum contracts, so a holder who bridges to Solana keeps the asset and silently loses the franchise. Nothing announces this at the bridge. It is a clean, checkable instance of a general problem catalogued under DAO metrics and analytics: a token's circulating supply and its votable supply are not the same number, and multi-chain expansion widens the gap.
Quantum Biology DAO votes on Snapshot, in the qbio.eth space: 29 proposals, 34 followers, quorum 13,500,000 QBIO. The whole record is public, and read end to end it is one of the more legible small-DAO case studies available – a complete arc from launch enthusiasm to a working oligarchy, in twenty months.
Turnout collapsed while voting power rose. The first three proposals, in January 2025, drew 46, 44 and 37 voters and decided 23.1, 25.7 and 16.6 million QBIO of voting power. Across the eleven proposals held in 2026, the median turnout is 11 voters and the low is 6 – against 34 space followers – while voting power per proposal has typically run 50 to 210 million. Both movements have the same cause: the retail cohort stopped showing up, and the large holders did not. This is the standard shape described in voter apathy, visible here at a scale small enough to count wallet by wallet.
Three wallets hold every vesting token, and all three run the space. Reading balanceOf on the vQBIO contract: the entire 150,000,000 vQBIO supply sits in exactly three addresses at 50,000,000 each – 0x47ed3d53…, 0x25e34eff… and 0x9f1d91ed… – and all three appear in the space's list of four administrators. Their liquid QBIO holdings are 200,001, 63,949 and 0 tokens respectively. Because Snapshot counts vQBIO at parity with QBIO, those three wallets carry 27.1% of the 553,844,211-token voting base (read 19 September 2026) on the strength of tokens they cannot sell. That is the inverse of what a vesting schedule is normally sold as doing: rather than deferring influence until a lock-up proves commitment, it grants full influence immediately and defers only the ability to exit. The general mechanism is covered in token unlocks and vesting schedules.
Both defeats have been budget votes, and the first budget passed anyway. Of 29 proposals, two have failed to carry. The first: DP-23, the Annual 2026 Budget, on 20 February 2026, rejected 152,776,435 against to 56,771,107 for. It also drew the highest turnout since launch week – 17 voters – and split the administrators: 0x47ed3d53… voted for, 0x25e34eff… against. Every one of the ten smallest voters backed it, contributing 348,896 votes between them, or 0.17% of everything cast. Over the four months that followed, the DAO passed the same budget in pieces: a Media Director in April, an Operations Budget in May, a Communications Budget in May, and a Comms/Events/Other Budget on 30 June – each unanimous, each on 6 to 11 voters. An omnibus that lost a contested vote became four line items that won uncontested ones.
The second defeat came on 19 August 2026, and it is the sharper one. DP-33, “Core Contributors August 2026” ran 16–19 August 2026 and was rejected 106,680,657 against to 641,985 for, with 50,289,061 abstaining, on 11 voters. Read wallet by wallet it is not a retail revolt. The largest ballot cast was 53,509,960 QBIO from 0xd9c6ee15… – a purely liquid holder, 13.2% of QBIO supply, no vQBIO, and not one of the space's four administrators – voting against. The second largest was 50,063,949 from the administrator 0x25e34eff…, also against.
The proposal's own author, the administrator 0x47ed3d53…, abstained with 50,200,001, and the third vesting wallet did not vote at all. A core-contributor budget was therefore defeated by one outside whale and one of the three insiders, with the insider who wrote it declining to back it. Quorum was never in question – 157,611,702 votes against a 13,500,000 floor – which makes the same point as the paragraph below from the other side: the threshold gates nothing, and the outcome turned entirely on which two large wallets showed up.
Quorum is arithmetic, not a guarantee. Proposals before late May 2025 carry a quorum of 1 (the first, 0); the 13,500,000 threshold appears from DP-19 onward. That threshold is 2.4% of the combined QBIO + vQBIO voting base – and it is not what actually gates outcomes, because any single one of the three vesting wallets clears it more than three times over on its own. When they sit out, the arithmetic is stark: DP-29, the 2026 Communications Budget, closed on 6 voters and 404,104 votes, or 3.0% of the stated quorum and 0.07% of the voting base, with a single wallet supplying 68.6% of it. A fixed-constant quorum set against a supply the constant does not track is a recurring design fault, not a local one.
The DAO has started formalising the concentration. On 11 June 2026 it passed DP-30, “Establish Large Token Holder Council” – 8 voters, 100,629,242 for, 50,214 against – and, on the same day with the same 8 voters, a Transparency and Reporting Measures proposal. Read together, the two are an honest read of the situation by the people in it: with turnout in single digits and three admin wallets holding a quarter of the votable supply, the DAO chose to name its large-holder body rather than pretend the general vote was deciding things.
Both halves paused, and both restarted. No proposal was posted between 5 August 2025 and 20 February 2026, a gap of six and a half months, and the ecosystem newsroom ran silent over almost exactly the same window (23 June 2025 to 21 April 2026). Governance then resumed at a steady clip – ten proposals between February and June 2026 – and the funded science continued regardless: the vote on DP-25, a six-month grant to the Institute carried on 16 April 2026 with 14 voters, and five days later the newsroom announced the $1.2 million grant.
On that vote, four wallets – the three vesting holders plus one 26.3-million-token address – supplied 99.8% of the voting power; the other ten voters supplied 0.2%. Two numbers in the proposal sequence, DP-18 and DP-22, have no Snapshot proposal at all, and the technical roadmap still reads “Version 1.0 | Latest update: 13 October 2024”. Checked on 19 September 2026, DP-33 is still the latest proposal, and the newsroom's latest post is the 1 May 2026 SynBioBeta notice.
Off-chain, the DAO organises through three working groups announced in May 2025: Science (reading and interpreting quantum-biology research for the community), Communications (outreach and education), and Operations (tracking contributor involvement and coordinating projects), each led by a designated contributor. The structure has been amended by vote more than once – a Working Groups proposal in January 2025, an update in May 2025, and a Science Working Group restructure carried on 17 May 2026 with 12 voters. Working groups are the standard answer to the coordination problem described in SubDAOs and working groups; here they carry more weight than usual, because they are where the contributors who cannot outvote the vesting holders actually do the work.
Within the Molecule / bio.xyz lineage, Quantum Biology DAO occupies a rare niche. Most BioDAOs are therapeutic-area DAOs that fund a pipeline toward a drug or intervention. Quantum Biology DAO is a foundational-science-and-tooling DAO: its deliverable is knowledge and an instrument, and its bet is that discovery upstream of any single disease unlocks many downstream applications. That places it closer in spirit to a research-infrastructure play than to a single-asset IP-NFT bet – a useful data point for anyone mapping how far the DeSci funding model can stretch beyond the drug-development template it was first built for.
It is also, on the evidence above, a useful data point about the governance half of DeSci. The science kept moving: a public dataset, a JCVI partnership, a funded lab in Los Angeles, a grant approved on schedule. The decentralization did not. Whether that matters depends on what the token was sold as – a claim on a research agenda, or a ticket to decide it.
Quantum Biology DAO is a science-funding organisation, not a governance protocol, so Caper is not a competing tool. But its record is a clean illustration of two things Caper's design takes a different position on.
The first is what a token is worth in a vote. In a caper a member's say depends on two things together: the tokens they hold and the votes they have earned, one for each ranked ballot they cast. Buying, selling or receiving tokens earns no votes, so a holding with no ballot behind it carries no weight, whatever it cost, and a block of tokens cannot carry a decision on its own. That is a different answer to the situation above, where a locked allocation counts at full strength from day one.
The second is what a disengaged holder can do instead of abstaining. In Caper the same weight that governs a vote also sets a member's share on exit, so leaving is a right written into the caper rather than a sale into whatever liquidity exists. A holder who no longer agrees with the direction is not left choosing between a vote that cannot move the outcome and a market that may not be there. See how Caper proposals work and how a caper raises funds.